Novartis AG (NVS) Given Consensus Recommendation of “Hold” by Brokerages

Novartis AG (NYSE:NVS) has received an average rating of “Hold” from the seventeen ratings firms that are currently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $83.19.

Several analysts have commented on the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis in a report on Tuesday, October 24th. Nord/LB restated a “neutral” rating on shares of Novartis in a report on Tuesday, January 2nd. Bank of America cut Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Leerink Swann lifted their price target on Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Finally, UBS Group restated a “neutral” rating on shares of Novartis in a report on Monday, January 15th.

Novartis (NYSE:NVS) traded up $1.83 during trading on Wednesday, reaching $85.43. The company had a trading volume of 1,374,388 shares, compared to its average volume of 1,721,517. The company has a current ratio of 1.21, a quick ratio of 0.91 and a debt-to-equity ratio of 0.31. The stock has a market cap of $221,650.00, a PE ratio of 26.25, a PEG ratio of 1.95 and a beta of 0.74. Novartis has a 1 year low of $72.67 and a 1 year high of $94.19.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Wednesday, January 24th. The company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.16 by $0.04. The company had revenue of $12.92 billion during the quarter, compared to analysts’ expectations of $12.65 billion. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The firm’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.14 EPS. equities research analysts predict that Novartis will post 5.36 EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. WFG Advisors LP grew its holdings in shares of Novartis by 38.1% during the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after purchasing an additional 337 shares during the period. Wealthcare Advisory Partners LLC purchased a new stake in shares of Novartis during the 3rd quarter worth about $106,000. Cable Hill Partners LLC lifted its position in Novartis by 588.8% during the 3rd quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock worth $112,000 after acquiring an additional 1,107 shares in the last quarter. Pinnacle Wealth Planning Services Inc. acquired a new position in Novartis during the 4th quarter worth approximately $113,000. Finally, Calton & Associates Inc. acquired a new position in Novartis during the 4th quarter worth approximately $118,000. Institutional investors and hedge funds own 11.06% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Novartis AG (NVS) Given Consensus Recommendation of “Hold” by Brokerages” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at

Novartis Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit